News
Home | News
WuXi AppTec’s Couvet Site Receives EcoVadis 2024 Silver Medal Rating
November 18, 2024Couvet, Switzerland – November 14, 2024 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries,…
WuXi AppTec Opens New R&D Center in Changzhou, China
November 14, 2024First operational building dedicated to API development for oligonucleotides, peptides, and complex synthetic conjugates. New facility enhances the Company’s drug substance process R&D capacity to drive innovation across all synthetic modalities and…
WuXi AppTec Breaks Ground on New Site in Singapore to Better Support Global Customers
May 23, 2024Photo caption (from left to right): Ms. Cindy Koh, Executive Vice President, Singapore Economic Development Board; Dr. Minzhang Chen, Co-CEO, WuXi AppTec; Mr. Heng Swee Keat, Deputy Prime Minister; Dr. Ge Li,…
A Successful PAI for a new Peptide Drug from Japan PMDA
April 9, 2024Our peptide manufacturing facility at Changzhou site has successfully passed the Pre-Approval Inspection by Japan Pharmaceuticals and Medical Devices Agency (PMDA) for an innovative peptide drug. The 3-day inspection, without any major…
2024 CDMO Leadership Awards
March 21, 2024Exciting moment! We’ve been honored with the 2024 CDMO Leadership Awards in all six core categories: Capabilities, Compatibility, Expertise, Quality, Reliability, and Service, again! Dr. Jinling Chen, our Senior Vice President and…
WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site
January 8, 2024Expansion Boosts Solid-Phase Peptide Synthesis Total Reactor Volume to 32,000 Liters in Response to Surging Demand Shanghai, China – January 8, 2024 — WuXi AppTec, a global company that provides a broad…
